Pharmaceutical Executive May 2, 2024
Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, weight issues, and type 2 diabetes, mainly in historically underrepresented groups.
Walgreens and Boehringer Ingelheim have announced a joint venture, which will focus on the growth of diversity and accessibility in clinical trials. As part of the collaboration, Walgreens will provide recruitment and trial sites for a Phase III clinical study targeting conditions such as obesity and type 2 diabetes for underrepresented groups, with Boehringer Ingelheim expected to strategically select specific Walgreens pharmacies to participate in the initiative. According to both companies, the collaboration aims to eradicate barriers, improve access, and offer equitable health representation in clinical trials, especially for Black and Hispanic...
Today's Sponsors
Today's Sponsor